OBJECTIVES: Proliferation indices are important prognostic factors for the clinical outcome of patients with mantle cell lymphoma (MCL). We investigated whether the expression of repp86 (restrictedly expressed proliferation-associated protein 86 kDa), a new proliferation specific marker expressed in the cell cycle phases G(2), S and M, but not in G(1), correlates with the clinical course in patients with MCL. PATIENTS AND METHODS: Biopsy specimens from 94 untreated patients enrolled in two multicenter trials were investigated immunohistochemically with monoclonal antibodies against CD20, CD5, CD3, CD23, cyclin D1, and repp86 (Ki-S2). RESULTS: Patients with 0-1% repp86 expression had a median overall survival time of 71.0 months, compared with 38.2 months for patients with 1-5% positive cells and 25.4 months for patients with 5-10% positive tumor cells. Patients with repp86 expression of more than 10% showed the shortest survival (median: 15.0 months). Kaplan-Meier analysis revealed a significant difference in the overall survival time between patients with very high (>10%) and very low (0-1%) repp86 expression (P < 0.0001) in the tumor cells. The multivariate analysis revealed repp86 expression to be superior to other clinical characteristics as a prognostic factor (P = 0.0016). CONCLUSION: Based on these findings, repp86 expression is a new important prognostic factor in MCL.
OBJECTIVES: Proliferation indices are important prognostic factors for the clinical outcome of patients with mantle cell lymphoma (MCL). We investigated whether the expression of repp86 (restrictedly expressed proliferation-associated protein 86 kDa), a new proliferation specific marker expressed in the cell cycle phases G(2), S and M, but not in G(1), correlates with the clinical course in patients with MCL. PATIENTS AND METHODS: Biopsy specimens from 94 untreated patients enrolled in two multicenter trials were investigated immunohistochemically with monoclonal antibodies against CD20, CD5, CD3, CD23, cyclin D1, and repp86 (Ki-S2). RESULTS:Patients with 0-1% repp86 expression had a median overall survival time of 71.0 months, compared with 38.2 months for patients with 1-5% positive cells and 25.4 months for patients with 5-10% positive tumor cells. Patients with repp86 expression of more than 10% showed the shortest survival (median: 15.0 months). Kaplan-Meier analysis revealed a significant difference in the overall survival time between patients with very high (>10%) and very low (0-1%) repp86 expression (P < 0.0001) in the tumor cells. The multivariate analysis revealed repp86 expression to be superior to other clinical characteristics as a prognostic factor (P = 0.0016). CONCLUSION: Based on these findings, repp86 expression is a new important prognostic factor in MCL.
Authors: Wolfram Klapper; Eva Hoster; Olaf Determann; Ilske Oschlies; Jeroen van der Laak; Françoise Berger; Heinz Wolfram Bernd; José Cabeçadas; Elias Campo; Sergio Cogliatti; Martin Leo Hansmann; Philip M Kluin; Roman Kodet; Yuri A Krivolapov; Christoph Loddenkemper; Harald Stein; Peter Möller; Thomas E F Barth; Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Stefano Pileri; Elisabeth Ralfkiaer; Grzegorz Rymkiewicz; Johan H van Krieken; Hans Heinrich Wacker; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling Journal: J Hematop Date: 2009-06-16 Impact factor: 0.196
Authors: C Schrader; D Janssen; W Klapper; J-U Siebmann; P Meusers; G Brittinger; M Kneba; M Tiemann; R Parwaresch Journal: Br J Cancer Date: 2005-10-17 Impact factor: 7.640
Authors: Steffen Blenk; Julia C Engelmann; Stefan Pinkert; Markus Weniger; Jörg Schultz; Andreas Rosenwald; Hans K Müller-Hermelink; Tobias Müller; Thomas Dandekar Journal: BMC Cancer Date: 2008-04-16 Impact factor: 4.430
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26